Recent studies show that circulating CD4+ T-cell subsets correlate with progression-free and overall survival in NSCLC patients receiving anti-PD-1 therapy, underscoring the value of immune cell profiling as a predictive tool [157]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.